The molecular mechanism underlying the acquisition of the antiestrogen-resistant phenotype in breast cancer
Breast Cancer, ISSN: 1340-6868, Vol: 5, Issue: 1, Page: 25-31
1998
- 2Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures2
- Readers2
Review Description
Breast cancer is thought to develope as an estrogen-dependent tumor. Approximately 30% of breast cancers can be treated by agents that block estrogen. However, all breast cancers have been known to acquire the hormone therapy-resistant phenotype with ultimate fatal results. Recent progress in breast cancer research has provided the important clues for elucidating the molecular mechanism of this conversion. The presence of the cross-talk between estrogen signaling and other mitogen-dependent signaling has been clarified at the estrogen receptor level. In addition, an estrogen-dependent transcriptional control mechanism has been characterized in detail. These breakthrough and the development of a pure antiestrogen would make it possible to consider the more sophisticated hormone therapy. In this review article, I summarized the current findings which seem to be essential in the treatment of breast cancer.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84858041860&origin=inward; http://dx.doi.org/10.1007/bf02967412; http://www.ncbi.nlm.nih.gov/pubmed/11091623; http://link.springer.com/10.1007/BF02967412; http://www.springerlink.com/index/pdf/10.1007/BF02967412; http://www.springerlink.com/index/10.1007/BF02967412; https://dx.doi.org/10.1007/bf02967412; https://link.springer.com/article/10.1007/BF02967412
Springer Nature
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know